Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

The Lancet

Volumn 373, Issue 9671, 2009, Pages 1253-1263

  Reid, David M ^a   Devogelaer, Jean Pierre ^b   Saag, Kenneth ^c   Roux, Christian ^d   Lau, Chak Sing ^e   Reginster, Jean Yves ^f   Papanastasiou, Philemon ^g   Ferreira, Alberto ^g   Hartl, Florian ^h   Fashola, Taiwo ^g   Mesenbrink, Peter ^g   Sambrook, Philip N ⁱ  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g NOVARTIS PHARMA AG   (Switzerland)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; ASTHMA; ATIRAL FIBRILLATION; BACKACHE; BLEPHARITIS; BLURRED VISION; BODY WEIGHT; BONE DENSITY; BONE NECROSIS; BONE PAIN; BRONCHITIS; CARDIAC DISORDER; CATARACT; CHILL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; EPISCLERITIS; FALLING; FATIGUE; FEMALE; FEVER; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOCALCEMIA; INFECTION; INFESTATION; INFLUENZA; INSOMNIA; ISCHIALGIA; JAW OSTEONECROSIS; JOINT SWELLING; KERATOCONJUNCTIVITIS SICCA; KIDNEY FUNCTION; LACRIMATION DISORDER; LIMB PAIN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL CHEST PAIN; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; MYALGIA; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; PARESTHESIA; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; RESPIRATORY TRACT DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN ALLERGY; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX DISEASE; THORAX PAIN; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VERTIGO; VOMITING;

EID: 64049104797     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60250-6     Document Type: Article

References (33)

1. Walsh L.J., Wong C.A., Pringle M., and Tattersfield A.E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313 (1996) 344-346
2. van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., and Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 (2000) 993-1000
3. van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., and Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39 (2000) 1383-1389
4. van Staa T.P., Leufkens H.G., and Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13 (2002) 777-787
5. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44 (2001) 1496-1503
6. Devogelaer J.P., Goemaere S., Boonen S., et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17 (2006) 8-19
7. van Staa T.P. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79 (2006) 129-137
8. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42 (1999) 2309-2318
9. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15 (2000) 1006-1013
10. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339 (1998) 292-299
11. Hamilton B., McCoy K., and Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14 (2003) 259-262
12. Cramer J.A., Lynch N.O., Gaudin A.F., Walker M., and Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28 (2006) 1686-1694
13. Cramer J.A., Gold D.T., Silverman S.L., and Lewiecki E.M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18 (2007) 1023-1031
14. Seeman E., Compston J., Adachi J., et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18 (2007) 711-719
15. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 (2006) 1013-1022
16. Briesacher B.A., Andrade S.E., Yood R.A., and Kahler K.H. Consequences of poor compliance with bisphosphonates. Bone 41 (2007) 882-887
17. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
18. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357 (2007) 1799-1809
19. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
20. Hollis B.W. The determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 89 (2004) 3149-3151
21. Genant H.K., Wu C.Y., van Kuijk C., and Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8 (1993) 1137-1148
22. Medical Dictionary for Regulatory Activities (MedDRA) (2003), Northrup Grumman, Reston, VA
23. WHO. Essential medicines. WHO model list (revised April 2003), 13th edn. http://whqlibdoc.who.int/hq/2003/a80290.pdf (accessed March 24, 2009).
24. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-208
25. Canalis E., Mazziotti G., Giustina A., and Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18 (2007) 1319-1328
26. van Staa T.P., Laan R.F., Barton I.P., Cohen S., Reid D.M., and Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48 (2003) 3224-3229
27. Wallach S., Cohen S., Reid D.M., et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67 (2000) 277-285
28. Melton III L.J., Lane A.W., Cooper C., Eastell R., O'Fallon W.M., and Riggs B.L. Prevalence and incidence of vertebral deformities. Osteoporos Int 3 (1993) 113-119
29. Kanis J.A., Stevenson M., McCloskey E.V., Davis S., and Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11 (2007) iii-iv ix-xi, 1-231.
30. Sambrook P.N., Kotowicz M., Nash P., et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18 (2003) 919-924
31. de Nijs R.N., Jacobs J.W., Lems W.F., et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355 (2006) 675-684
32. Saag K.G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357 (2007) 2028-2039
33. Strampel W., Emkey R., and Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30 (2007) 755-763